DE69409237D1 - Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten - Google Patents

Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Info

Publication number
DE69409237D1
DE69409237D1 DE69409237T DE69409237T DE69409237D1 DE 69409237 D1 DE69409237 D1 DE 69409237D1 DE 69409237 T DE69409237 T DE 69409237T DE 69409237 T DE69409237 T DE 69409237T DE 69409237 D1 DE69409237 D1 DE 69409237D1
Authority
DE
Germany
Prior art keywords
peptide
protein
antibody
pharmaceutical compositions
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69409237T
Other languages
English (en)
Other versions
DE69409237T2 (de
Inventor
Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Application granted granted Critical
Publication of DE69409237D1 publication Critical patent/DE69409237D1/de
Publication of DE69409237T2 publication Critical patent/DE69409237T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule
DE69409237T 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten Expired - Fee Related DE69409237T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions
PCT/GB1994/001201 WO1994028879A1 (en) 1993-06-03 1994-06-02 Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads

Publications (2)

Publication Number Publication Date
DE69409237D1 true DE69409237D1 (de) 1998-04-30
DE69409237T2 DE69409237T2 (de) 1998-10-29

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69409237T Expired - Fee Related DE69409237T2 (de) 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Country Status (9)

Country Link
EP (1) EP0707473B1 (de)
AT (1) ATE164311T1 (de)
AU (1) AU6804394A (de)
DE (1) DE69409237T2 (de)
DK (1) DK0707473T3 (de)
ES (1) ES2117272T3 (de)
GB (1) GB9311454D0 (de)
WO (1) WO1994028879A1 (de)
ZA (1) ZA943920B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
CN101428006A (zh) 2000-09-28 2009-05-13 诺华疫苗和诊断公司 微粒体组合物及其生产方法
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
EP2390270A1 (de) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutische Polypeptide, Homologe davon, Fragmente davon und Verwendung bei modulierender plättchenvermittelter Aggregation
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles

Also Published As

Publication number Publication date
WO1994028879A1 (en) 1994-12-22
EP0707473A1 (de) 1996-04-24
ES2117272T3 (es) 1998-08-01
DE69409237T2 (de) 1998-10-29
ZA943920B (en) 1995-12-04
DK0707473T3 (da) 1999-01-04
ATE164311T1 (de) 1998-04-15
EP0707473B1 (de) 1998-03-25
GB9311454D0 (en) 1993-07-21
AU6804394A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
DE69230670D1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
NO962346L (no) Humaniserte antistoffer og anvendelser derav
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
DE69428040D1 (de) Orale darreichungsform
DE69409237D1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DK235687D0 (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
FR2577557B1 (fr) Peptides et derives peptidiques, leur preparation, leur utilisation en therapeutique et compositions pharmaceutiques les contenant
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DK0614910T3 (da) Renset form af streptograminer, dens fremstilling og farmaceutiske præparater indeholdende denne form
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
DE69002881D1 (de) Peptide und deren Benutzung.
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드
PT840794E (pt) Medicamento contendo pelo menos uma parte da proteina ul84 do citomegalovirus, utilizacao de polipeptideos de acordo com a sequencia do aminoacido da proteina ul84 e processo para a introducao de ul84 em celulas alvo
IT8947833A0 (it) Peptidi somatostatinici, procedimento per la loro produzione, preparati farmaceutici che li contengono e loro uso come medicamenti
ATE4196T1 (de) Ovulation stimulierende peptide und deren pharmazeutische zusammensetzungen.
ATE6639T1 (de) Ein gereinigtes polypeptid, ein verfahren zu dessen herstellung, dessen anwendung und das enthaltende pharmazeutische praeparat.
BR1100801A (pt) Proteìna, peptìdeo, proteìna ou peptìdeo, sequência de dna, processo para a preparação de uma proteìna ou peptìdeo, anticorpo, composição farmacêutica, e, uso de uma proteìna ou peptìdeo
IT8622051A0 (it) Composizioni farmaceutiche adattivita' cicatrizzante.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee